Skip to main content
Fig. 7 | Breast Cancer Research

Fig. 7

From: Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers

Fig. 7

Poorer prognosis for luminal A breast cancer and triple negative breast cancer (TNBC) patients is associated with low expression of CREB3L1. Kaplan–Meier relapse-free survival probability for breast cancer patients with high (red) and low (black) CREB3L1 gene expression (divided at the median). The online software, KM plotter, was used to access gene expression data and relapse-free survival information from Gene Expression Omnibus (Affymetrix microarrays only), European Genome-phenome Archive and The Cancer Genome Atlas. The two patient cohorts were compared and the hazard ratio (HR) with 95 % confidence intervals and log-rank p value were calculated for the low versus high CREB3L1 levels. Relapse-free survival probability for breast cancer patients: all (a; n = 3554), luminal A (b; n = 1764), luminal B (c; n = 1002), human epidermal growth factor receptor 2 (HER2) amplified (d; n = 208) and triple negative (e; n = 580) divided into low or high CREB3L1 mRNA expression groups

Back to article page